Carcinoma, Squamous
9
1
2
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
22.2%
2 terminated out of 9 trials
33.3%
-53.2% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
Clinical Study Protocol for Cutaneous SCC for Immunocompromised Patients
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
ctDNA and MRI Parameters in Head and Neck Cancer
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment